Viela Bio, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY20 | FY19 | FY18 | |
|---|---|---|---|
| Revenue | $11.7M | $50.0M | — |
| Operating income | −$153.9M | −$89.7M | −$192.3M |
| Net income | −$150.7M | −$86.4M | −$190.3M |
| Total assets | $423.3M | $384.1M | $139.8M |
| Total liabilities | $47.4M | $29.5M | — |
| Equity | $375.8M | $354.5M | −$188.4M |
| EPS (diluted) | — | — | — |
| Shares out. | 51.0M | 50.6M | 10 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2020- Operating margin
- −1320.6%
- Net margin
- −1293.1%
- Return on equity
- −40.1%
- Return on assets
- −35.6%
- Return on capital (ROCE)
- −40.8%
- Liabilities / assets
- 11.2%
- Debt / equity
- 0.13×
- Book value / share
- $7.37
- Revenue growth (YoY)
- −76.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2020- Altman Z″ (distress)
- 7.91safe
- Accruals / assets
- −10.5%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 4 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- UPLIZNAJun 11, 2020
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Cao YanlingDirector | Mar 13, 2021 | D | 8.3M | $53.00 |
| Astrazeneca Plc10% owner | Mar 15, 2021 | U | 14.7M | $53.00 |
| Wicki AndreasDirector | Mar 13, 2021 | D | 1.8M | $53.00 |
| Hu EdwardDirector | Mar 13, 2021 | D | 4.0M | $53.00 |
| Boundless Meadow Ltd10% owner | Mar 13, 2021 | U | 8.3M | $53.00 |
| Chan MitchellOfficer — Chief Financial Officer | Mar 13, 2021 | D | 37,500 | $53.00 |
| Drappa JornOfficer — Chief Medical Officer | Mar 13, 2021 | D | 202,661 | $53.00 |
| Ragatz WilliamOfficer — Senior VP, Head of Commercial | Mar 13, 2021 | D | 16,250 | $53.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 15, 2021
- Director / officer changeMar 4, 2021
- Results of operationsMar 1, 2021
- Results of operationsFeb 16, 2021
- Entered a material agreement · Director / officer change · Other material eventFeb 1, 2021
- Director / officer changeDec 8, 2020
- Results of operationsNov 10, 2020
- Other material eventNov 5, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12BMar 25, 2021
- SC 13D/AMar 17, 2021
- 4FORM 4 SUBMISSIONMar 16, 2021
- 4Mar 16, 2021
- 4Mar 16, 2021
- 4Mar 15, 2021
- 4FORM 4 SUBMISSIONMar 15, 2021
- 4Mar 15, 2021
- 4FORM 4 SUBMISSIONMar 15, 2021
- 4FORM 4 SUBMISSIONMar 15, 2021
- 4FORM 4 SUBMISSIONMar 15, 2021
- S-8 POSMar 15, 2021
- 4FORM 4 SUBMISSIONMar 15, 2021
- 4FORM 4 SUBMISSIONMar 15, 2021
- 4FORM 4 SUBMISSIONMar 15, 2021
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.